John Shillingford, PhD holds both a B.Sc. in Biochemistry and a Ph.D. in Biochemical Pharmacology.
John`s career across pharmaceutical, medical device and CRO sectors has stretched over 40 years. John has both lived and worked in several European Countries as well as the USA. His wide experience of drug and medical device development has been acquired during the management of both clinical and data operations for major global programmes. A major focus has been to successfully commence and manage operations across Central and Eastern Europe and integrate these research units into global corporate operations.
John has worked in all phases of drug development and medtech user evaluations, managing clinical research projects in Eastern and Western Europe, North America and Japan. John’s experience includes the development of a number of novel medical devices, including the treatment of cardiovascular and central nervous systems, and a range of medical devices to attenuate pain, the treatment of cerebral clots and various other medtech diagnostic equipment.
His reputation for the planning and execution of medical device clinical studies has seen John lead c. five medtech devices and thirty biotech projects to market. Most recently his successes have included a leading project on Transcranial Ultrasound (TUS) therapy for stroke victims, Transdermal Electrical Neurostimulation (TENS) studies to modulate nerves for chronic pain, and a series of bone augmentation devices for use within both dental and limb treatments.
John is an accomplished speaker and trainer and has presented at major international conferences. In addition to his work on the Arterial portfolio businesses, he currently has responsibility for a number of international regulatory courses on pharmaceutical and medical device companies legal responsibilities to groups in the USA, Europe and South East Asia.